Presence of FISH abnormalities is associated with plasma cell burden in light chain amyloidosis

Publication date: Available online 16 August 2017
Source:Hematology/Oncology and Stem Cell Therapy
Author(s): Lindsay Hammons, Ruta Brazauskas, Marcelo Pasquini, Mehdi Hamadani, Parameswaran Hari, Anita D'Souza
Objective/BackgroundTo assess abnormalities found on CD138-enriched fluorescent in situ hybridization (FISH) studies on pretreated bone marrow in systemic amyloid light-chain (AL) amyloidosis and correlate findings between these abnormalities with organ involvement and 1-year survival.MethodsWe reviewed 107 patients with systemic AL to identify the impact of a diagnostic FISH study done on plasma cell clones in our institution between January 2010 and January 2015; 77 had pretreatment testing performed.ResultsA total of 77 (61%) patients had abnormal FISH including: (1) hyperdiploidy (29%), t(11;14), (20%); (2) hypodiploidy (16%), t(4;14), (1%), del17p (5%), and +1q21 (5%). Abnormal FISH studies were more likely in those patients with plasma cell involvement ≥10% (p = .002). FISH abnormalities were not shown to correlate with stage, cardiac involvement, or survival at 1 year. One-year survival was significantly affected by stage at diagnosis and presence of cardiac and hepatic amyloid involvement.ConclusionWe conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival.



http://ift.tt/2wjeFOH